Skip to content
OpenCapital
Get started

Karyopharm Therapeutics KPTI Q4 2024 Annual earnings

Reported February 19, 2025 · Before market open

Revenue$30.5MMiss by $7.3M
EPS-$3.60Beat by $0.30
Revenue estimate$37.8M
EPS estimate-$3.90

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$33.6M
EPS estimate-$1.31

Versus estimates

Revenue

Q1 2026$35.1MBeat by $3.7MQ4 2025$34.1MMiss by $1.0MQ3 2025$44.0MBeat by $2.0MQ2 2025$37.9MMiss by $1.6MQ1 2025$30.0MMiss by $5.1M
Q4 2024$30.5MMiss by $7.3M

Diluted EPS

Q1 2026-$1.24Beat by $0.21Q4 2025-$3.60Miss by $1.34Q3 2025-$3.82Miss by $0.35Q2 2025-$4.32Miss by $0.52Q1 2025-$2.77Beat by $1.44
Q4 2024-$3.60Beat by $0.30

Ask the moment Karyopharm Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Karyopharm Therapeutics report Q4 2024 earnings?
Karyopharm Therapeutics (KPTI) reported Q4 2024 earnings on February 19, 2025 before market open.
What were Karyopharm Therapeutics's Q4 2024 revenue and EPS?
Karyopharm Therapeutics reported revenue of $30.5M and eps of $-3.60 for Q4 2024.
Did Karyopharm Therapeutics beat estimates in Q4 2024?
Revenue missed the consensus estimate of $37.8M by $7.3M. EPS beat the consensus estimate of $-3.90 by $0.30.
Where can I find Karyopharm Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-022765) directly on SEC EDGAR. The filing index links above go to sec.gov.